RE
REGN
Quarter ended Sep 30, 2023 · FY2023 Q3

Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Sep 30, 2023

Revenue for the quarter increased compared to the prior quarter. Revenue also rose compared to the same quarter one year earlier.

Key takeaway

Quarter ended Sep 30, 2023 · FY2023 Q3

Revenue for the quarter increased compared to the prior quarter. Revenue also rose compared to the same quarter one year earlier.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$3.4B

Revenue reported for this quarter.

Quarter-over-quarter

+6.5%

Change from the immediately preceding quarter.

Year-over-year

+14.5%

Change from the comparable year-ago quarter.

Trailing four quarters

$13.1B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Dec 31, 2022$3.4B-31.0%
Mar 31, 2023$3.2B+6.6%
Jun 30, 2023$3.2B+10.5%
Sep 30, 2023$3.4B+14.5%

Revenue performance

The reported revenue direction is upward for the current quarter.

Quarterly comparison

Revenue was higher than the immediately preceding quarter. Revenue was also higher than the same quarter one year ago.

What to watch

No filing context is provided to identify specific factors affecting revenue.

Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Sep 30, 2023